We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$11.9M
Cap. Flow
+$20M
Cap. Flow %
4.38%
Top 10 Hldgs %
47.78%
Holding
85
New
14
Increased
34
Reduced
11
Closed
24

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$18M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$14.6M
3
VRNA
Verona Pharma
VRNA
+$6.28M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.17M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.11M

Top Sells

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$14M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.84M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$6.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.4M
5
ADCT icon
ADC Therapeutics
ADCT
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
2 Miscellaneous 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$31.3M 6.85%
400,014
+28,573
+8% +$2.67M
MRUS
2
DELISTED
Merus
MRUS
$28.6M 6.26%
680,845
+45,406
+7% +$2.18M
INSM icon
3
Insmed
INSM
$27.3B
$25.7M 5.62%
372,230
+24,535
+7% +$1.77M
VRNA
4
DELISTED
Verona Pharma
VRNA
$24M 5.24%
516,014
+167,148
+48% +$6.28M
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$20.6M 4.5%
739,563
+99,723
+16% +$3.02M
VCYT icon
6
Veracyte
VCYT
$3.41B
$19.9M 4.36%
503,281
+32,716
+7% +$1.24M
ERAS icon
7
Erasca
ERAS
$5.69B
$18.9M 4.14%
7,543,901
+597,413
+9% +$1.64M
PLRX icon
8
Pliant Therapeutics
PLRX
$70.6M
$17.3M 3.79%
+1,315,601
New +$18M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.78B
$16.3M 3.56%
1,230,400
+851,654
+225% +$14.6M
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$15.8M 3.46%
543,651
+68,096
+14% +$2.85M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7.01B
$15.3M 3.35%
273,896
+18,318
+7% +$1.01M
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15M 3.27%
179,085
+11,975
+7% +$984K
URGN icon
13
UroGen Pharma
URGN
$2.14B
$11.9M 2.61%
1,120,473
+219,344
+24% +$2.63M
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
$10M 2.19%
598,952
-145,640
-20% -$2.41M
KOD icon
15
Kodiak Sciences
KOD
$2.2B
$9.95M 2.18%
1,000,000
+500,000
+100% +$2.87M
PSTX
16
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$9.72M 2.13%
1,012,307
-2,675,241
-73% -$14M
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.31B
$9.51M 2.08%
1,178,300
+78,810
+7% +$723K
TELA icon
18
TELA Bio
TELA
$37.3M
$9.26M 2.03%
3,065,649
+1,940,721
+173% +$5.46M
SRRK icon
19
Scholar Rock
SRRK
$6.99B
$7.92M 1.73%
+183,243
New +$5.97M
WVE icon
20
Wave Life Sciences
WVE
$968M
$7.53M 1.65%
608,897
-18,655
-3% -$249K
COGT icon
21
Cogent Biosciences
COGT
$6.12B
$7.18M 1.57%
921,137
-300,225
-25% -$2.99M
ASND icon
22
Ascendis Pharma A/S
ASND
$17.7B
$7.09M 1.55%
51,491
+46,491
+930% +$6.11M
IRON icon
23
Disc Medicine
IRON
$2.95B
$7M 1.53%
110,381
+6,519
+6% +$377K
CLDX icon
24
Celldex Therapeutics
CLDX
$3.07B
$6.69M 1.46%
264,560
+119,560
+82% +$3.25M
ELUT icon
25
Elutia
ELUT
$36.8M
$6.67M 1.46%
1,782,271
+136,463
+8% +$529K
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Silverarc Capital Management held 85 positions worth $457M, up 2.7% from $445M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $20M of net new capital in Q4 2024, opening 14 new positions and adding to 34 existing holdings. Its largest new stake was Pliant Therapeutics: 1,315,601 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Poseida Therapeutics, Inc. Common Stock, an estimated $14M trimmed.

  • Silverarc Capital Management's largest Q4 2024 buy was Pliant Therapeutics: 1,315,601 shares worth $17.3M.
  • Silverarc Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $14.6M increase.
  • Silverarc Capital Management's biggest Q4 2024 reduction was Poseida Therapeutics, Inc. Common Stock, cutting an estimated $14M.
  • Silverarc Capital Management fully exited Alnylam Pharmaceuticals in Q4 2024, selling an estimated $9.84M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $457M portfolio in Q4 2024.
  • Silverarc Capital Management opened 14 new positions and closed 24 in Q4 2024.
  • Silverarc Capital Management's portfolio value rose 2.7% quarter-over-quarter to $457M.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.